
About this episode
JACC's July 29 issue explores why the ACURATE neo2 valve failed in its IDE trial, with a post-hoc analysis pointing to under-expansion in heavily calcified anatomies as a potential culprit. Though the valve is off the market, the findings raise critical questions about procedural success, device design, and future innovation in TAVR. Listen to our Deep Dive narrated by JACC Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC, as he goes into the science behind the peer review.
Get every episode summarized
Each time JACC This Week publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from JACC This Week

March 10, 2026: Inside JACC Stats: The State of CV Health in Focus | JACC this W...
JACC This Week

March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inh...
JACC This Week

February 24, 2026: ACHD Guideline in Focus—From Survival to Stewardship | JACC T...
JACC This Week

February 17, 2026: Women's Cardiovascular Health in Focus: From Inclusion to Red...
JACC This Week